Reimagining Medicine
Company overview
Innovation: Pipeline overview
Cardiovascular
Financial review
Immunology
LNA043-ANGPTL3 agonist
2023 priorities
Innovation: Clinical trials
Neuroscience
NCT04864392 ONWARDS (CLNA043A12202)
Knee osteoarthritis
Phase 2
Indication
Phase
Patients
550
Primary
Outcome
Measures
Arms
Intervention
Target
Patients
Change from baseline in the cartilage thickness of the medial compartment of
the knee as assessed by imaging
LNA043 injection to the knee with dosing regimen A
LNA043 injection to the knee with dosing regimen B
LNA043 injection to the knee with dosing regimen C
LNA043 injection to the knee with dosing regimen D
Placebo injection to the knee
Patients with Symptomatic knee osteoarthritis
Primary 2024
Readout
Milestone(s)
Publication
TBD
Oncology
Appendix
Abbreviations
Other
74 Investor Relations | Q4 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation